Additional Information
| Category | Details |
| Brand Name | Zacco |
| Generic Name | Clobazam |
| Therapeutic Class | Antiepileptic / Anxiolytic (Benzodiazepine class) |
| Formulation | Oral Suspension |
| Strengths Available | 5 mg/5 ml and 10 mg/5 ml |
| Presentation | Oral suspension supplied in amber glass bottles (100 ml and 150 ml) with child-resistant cap, 5 ml oral syringe, and adaptor |
| Active Ingredient | Clobazam BP/Ph.Eur |
| Pharmacological Class | Benzodiazepine derivative with anxiolytic, sedative, muscle relaxant, and anticonvulsant properties |
| Mechanism of Action | Enhances the effect of gamma-aminobutyric acid (GABA) in the brain, producing a calming and anticonvulsant effect |
| Indications | – Short-term treatment of symptoms of severe anxiety in adults – Adjunctive therapy in epilepsy (fits) in adults and children aged over 2 years – Short-term treatment of hyperarousal and agitation in patients with schizophrenic or other psychotic illness (in combination with other treatments) |
| Route of Administration | Oral |
| Dosage Form | Suspension (for oral use only) |
| Storage Conditions | No special storage conditions required. Use within 60 days of first opening. Keep out of reach of children. |
| Formulation Features | Sugar-free, alcohol-free, and unflavoured |
| Packaging | Bottle pack with leaflet, oral syringe, and adaptor |
| Manufacturer | Delpharm Bladel B.V., Industrieweg 1, 5531 AD, Bladel, Netherlands |
| Marketing Authorisation Holder (MAH) | Thame Laboratories, Unit 4, Bradfield Road, Ruislip, Middlesex, HA4 0NU, United Kingdom |
| Prescription Status | Prescription Only Medicine (POM) |
| Country of Origin | United Kingdom |
| Regulatory Status | Registered and approved for marketing in Bahrain; distributed and marketed across MENA & GCC regions through Pharma Solutions |
Related Products
Related products
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.